Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANPARIO PLC Share Issue/Capital Change 2019

Jul 17, 2019

7489_rns_2019-07-17_cd17f8f5-f014-4e9c-ba94-fd633455bba9.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8397F

Anpario PLC

17 July 2019

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 17 July 2019

Name of applicant: Anpario plc
Name of scheme: SAYE Share Scheme

EMI Share Scheme

Unapproved Share Scheme
Period of return: From: 17 January 2019 To: 16 July 2019
Balance of unallotted securities under scheme(s) from previous return: SAYE Share Scheme - 40,134

EMI Share Scheme - 426,173

Unapproved Share Scheme - 71,524
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): SAYE Share Scheme - NIL

EMI Share Scheme - NIL

Unapproved Share Scheme - NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): SAYE Share Scheme - NIL

EMI Share Scheme - 50,000

Unapproved Share Scheme - NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period: SAYE Share Scheme - 40,134

EMI Share Scheme - 376,173

Unapproved Share Scheme - 71,524
Name of contact: Karen Prior / John Butlin
Telephone number of contact: 01909 537380

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLREANXXFDPNEEF